Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

Claudio Vernieri; Michele Prisciandaro; Monica Milano; Maria Silvia Cona; Claudia Maggi; Marta Brambilla; Alessia Mennitto; Chiara Fabbroni; Elena Farè; Sara Cresta; Luigi Celio; Gabriella Mariani; Giulia Bianchi; Giuseppe Capri; Filippo de Braud

doi:10.1016/j.clbc.2018.12.004

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

Claudio Vernieri, Michele Prisciandaro, Monica Milano, Maria Silvia Cona, Claudia Maggi, Marta Brambilla, Alessia Mennitto, Chiara Fabbroni, Elena Farè, Sara Cresta, Luigi Celio, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud

Research output: Contribution to journal › Article

Abstract

Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.

Original language	English
Pages (from-to)	e306-e318
Journal	Clinical Breast Cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.clbc.2018.12.004
Publication status	Published - Apr 2019

Keywords

Adverse events
Metastatic breast cancer
Objective response rate
Overall survival
Progression-free survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.clbc.2018.12.004

Fingerprint Dive into the research topics of 'Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles'. Together they form a unique fingerprint.

Cite this

Vernieri, C., Prisciandaro, M., Milano, M., Cona, M. S., Maggi, C., Brambilla, M., Mennitto, A., Fabbroni, C., Farè, E., Cresta, S., Celio, L., Mariani, G., Bianchi, G., Capri, G., & de Braud, F. (2019). Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. Clinical Breast Cancer, 19(2), e306-e318. https://doi.org/10.1016/j.clbc.2018.12.004

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : A Retrospective Comparison of Efficacy and Safety Profiles. / Vernieri, Claudio; Prisciandaro, Michele; Milano, Monica; Cona, Maria Silvia; Maggi, Claudia; Brambilla, Marta; Mennitto, Alessia; Fabbroni, Chiara; Farè, Elena; Cresta, Sara ; Celio, Luigi ; Mariani, Gabriella ; Bianchi, Giulia ; Capri, Giuseppe ; de Braud, Filippo.

In: Clinical Breast Cancer, Vol. 19, No. 2, 04.2019, p. e306-e318.

Research output: Contribution to journal › Article

Vernieri, C, Prisciandaro, M, Milano, M, Cona, MS, Maggi, C, Brambilla, M, Mennitto, A, Fabbroni, C, Farè, E, Cresta, S , Celio, L , Mariani, G , Bianchi, G , Capri, G & de Braud, F 2019, 'Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles', Clinical Breast Cancer, vol. 19, no. 2, pp. e306-e318. https://doi.org/10.1016/j.clbc.2018.12.004

Vernieri, Claudio ; Prisciandaro, Michele ; Milano, Monica ; Cona, Maria Silvia ; Maggi, Claudia ; Brambilla, Marta ; Mennitto, Alessia ; Fabbroni, Chiara ; Farè, Elena ; Cresta, Sara ; Celio, Luigi ; Mariani, Gabriella ; Bianchi, Giulia ; Capri, Giuseppe ; de Braud, Filippo. / Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : A Retrospective Comparison of Efficacy and Safety Profiles. In: Clinical Breast Cancer. 2019 ; Vol. 19, No. 2. pp. e306-e318.

@article{72f5b9a740f044ff86c55f35ae6d07c9,

title = "Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles",

abstract = "Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.",

keywords = "Adverse events, Metastatic breast cancer, Objective response rate, Overall survival, Progression-free survival",

author = "Claudio Vernieri and Michele Prisciandaro and Monica Milano and Cona, {Maria Silvia} and Claudia Maggi and Marta Brambilla and Alessia Mennitto and Chiara Fabbroni and Elena Far{\`e} and Sara Cresta and Luigi Celio and Gabriella Mariani and Giulia Bianchi and Giuseppe Capri and {de Braud}, Filippo",

year = "2019",

month = apr,

doi = "10.1016/j.clbc.2018.12.004",

language = "English",

volume = "19",

pages = "e306--e318",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer

T2 - A Retrospective Comparison of Efficacy and Safety Profiles

AU - Vernieri, Claudio

AU - Prisciandaro, Michele

AU - Milano, Monica

AU - Cona, Maria Silvia

AU - Maggi, Claudia

AU - Brambilla, Marta

AU - Mennitto, Alessia

AU - Fabbroni, Chiara

AU - Farè, Elena

AU - Cresta, Sara

AU - Celio, Luigi

AU - Mariani, Gabriella

AU - Bianchi, Giulia

AU - Capri, Giuseppe

AU - de Braud, Filippo

PY - 2019/4

Y1 - 2019/4

N2 - Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.

AB - Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.

KW - Adverse events

KW - Metastatic breast cancer

KW - Objective response rate

KW - Overall survival

KW - Progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85059582368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059582368&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.12.004

DO - 10.1016/j.clbc.2018.12.004

M3 - Article

C2 - 30635175

AN - SCOPUS:85059582368

VL - 19

SP - e306-e318

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -